Bronchogen vs Thymulin
A side-by-side research comparison of Bronchogen and Thymulin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Bronchogen | Thymulin |
|---|---|---|
| Full name | Bronchogen (Ala-Asp-Glu-Leu Bronchopulmonary Bioregulator) | Thymulin (Facteur Thymique Serique) |
| Category | Immune Support | Immune Support |
| Status | Research compound (peptide bioregulator) | Research compound |
| Mechanism | As a signal peptide (Ala-Asp-Glu-Leu), it is proposed to regulate gene expression in respiratory epithelial tissue, supporting airway lining integrity, antioxidant defense, and local respiratory immune function. | Binds to specific receptors on T-cell precursors promoting their differentiation into mature T-cells, modulates cytokine production, and requires zinc as cofactor. |
| Molecular weight | ~445 Da | 847.9 Da |
| Half-life | Short (peptide) | ~2 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~80% subcutaneous |
| Typical dose | ~1-2 capsules/day or short injectable courses | 1-5 mg |
| Frequency | Once daily | 2-3x per week |
| Route | Oral capsule or subcutaneous | Subcutaneous injection |
Bronchogen reported benefits
- Respiratory/airway support
- Bronchopulmonary tissue maintenance (proposed)
- Local respiratory immune support
- Short course-based protocol
Thymulin reported benefits
- T-cell maturation support
- Thymic function restoration
- Zinc-dependent immune activation
- Anti-inflammatory properties
Related comparisons
Research and educational reference only. Not medical advice.